Siplizumab (CD2/LFA-2) - Biosimilar Research Grade
Gecertificeerd

Siplizumab (CD2/LFA-2) - Biosimilar Research Grade

Catalog #: 10-088
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Siplizumab has been shown to cause depletion of T-cells.It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers.In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.

Swiss Prot

P06729, Q53F96

Immunogen

Humanized / CD2/LFA-2 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

MEDI-507, CD2/LFA-2, CD2/LFA-2

Beschrijving

Siplizumab (CD2/LFA-2) - Biosimilar Research Grade Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamSiplizumab (CD2/LFA-2) - Biosimilar Research Grade
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-088